Wills Financial Group LLC Boosts Stock Position in Pfizer Inc. $PFE

Wills Financial Group LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 906.4% in the fourth quarter, Holdings Channel reports. The fund owned 109,153 shares of the biopharmaceutical company’s stock after purchasing an additional 98,307 shares during the period. Wills Financial Group LLC’s holdings in Pfizer were worth $2,718,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Horizon Financial Services LLC lifted its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the 4th quarter valued at $26,000. YANKCOM Partnership purchased a new position in Pfizer during the 4th quarter worth $28,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the period. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.2%

NYSE:PFE opened at $25.67 on Wednesday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $26.56 and a 200-day simple moving average of $26.31. The company has a market capitalization of $146.28 billion, a PE ratio of 19.59 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the firm posted $0.92 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded HYMPAVZI’s label to include additional hemophilia A and B patient groups, including pediatric patients ages 6 to 11, which could deepen Pfizer’s rare-disease revenue opportunity and strengthen its growth story. U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
• Positive Sentiment: Pfizer’s obesity drug showed about 16% weight loss in a Phase 2b study, adding to hopes that the company can build a meaningful presence in the lucrative weight-loss market. Pfizer’s Obesity Drug Shows 16% Weight Loss In Phase 2b Study
• Positive Sentiment: Traders bought a high volume of Pfizer call options, suggesting some investors are positioning for further upside. Investors Buy High Volume of Pfizer Call Options (NYSE:PFE)
• Neutral Sentiment: Commentary pieces argued Pfizer still has long-term upside and could eventually double over several years, but these were opinion-based and did not present a new fundamental catalyst. Prediction: Pfizer Stock Will Double on This Date
• Neutral Sentiment: Pfizer was also mentioned in broader sector commentary about pharma companies needing to acquire new assets as patent cliffs approach, which is more of an industry backdrop than a direct stock-moving event. BMO Capital Sticks to Their Buy Rating for Pfizer (PFE)
• Negative Sentiment: Despite recent progress, Pfizer still faces investor concern over post-COVID growth normalization and patent-expiration pressure, which has kept enthusiasm muted relative to peers. Will obesity drugs save Pfizer from its post-COVID slump?

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PFE. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Guggenheim raised their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.